Open Access Original research

Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans

Miho Shidahara12*, Manabu Tashiro2, Nobuyuki Okamura3, Shozo Furumoto3, Katsutoshi Furukawa4, Shoichi Watanuki2, Kotaro Hiraoka2, Masayasu Miyake2, Ren Iwata5, Hajime Tamura1, Hiroyuki Arai4, Yukitsuka Kudo6 and Kazuhiko Yanai23

Author Affiliations

1 Division of Medical Physics, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan

2 Division of Cyclotron Nuclear Medicine, Cyclotron Radioisotope Center, Tohoku University, Sendai, 980-8578, Japan

3 Department of Pharmacology, Tohoku University School of Medicine, Sendai, 980-8575, Japan

4 Department of Geriatrics and Gerontology, Division of Brain Sciences, Institute of Development, Aging and Cancer, Tohoku University, Sendai, 980-8575, Japan

5 Division of Radiopharmaceutical Chemistry, Cyclotron Radioisotope Center, Tohoku University, Sendai, 980-8578, Japan

6 Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, 980-8574, Japan

For all author emails, please log on.

EJNMMI Research 2013, 3:32  doi:10.1186/2191-219X-3-32

Published: 24 April 2013

Abstract

Background

The biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe ([18F] FACT) was investigated in humans.

Methods

Six healthy subjects (three males and three females) were enrolled in this study. An average of 160.8 MBq of [18F] FACT was intravenously administered, and then a series of whole-body PET scans were performed. Nineteen male and 20 female source organs, and the remainder of the body, were studied to estimate time-integrated activity coefficients. The mean absorbed dose in each target organ and the effective dose were estimated from the time-integrated activity coefficients in the source organs. Biodistribution data from [18F] FACT in mice were also used to estimate absorbed doses and the effective dose in human subjects; this was compared with doses of [18F] FACT estimated from human PET data.

Results

The highest mean absorbed doses estimated using human PET data were observed in the gallbladder (333 ± 251 μGy/MBq), liver (77.5 ± 14.5 μGy/MBq), small intestine (33.6 ± 30.7 μGy/MBq), upper large intestine (29.8 ± 15.0 μGy/MBq) and lower large intestine (25.2 ± 12.6 μGy/MBq). The average effective dose estimated from human PET data was 18.6 ± 3.74 μSv/MBq. The highest mean absorbed dose value estimated from the mouse data was observed in the small intestine (38.5 μGy/MBq), liver (25.5 μGy/MBq) and urinary bladder wall (43.1 μGy/MBq). The effective dose estimated from the mouse data was 14.8 μSv/MBq for [18F] FACT.

Conclusions

The estimated effective dose from the human PET data indicated that the [18F] FACT PET study was acceptable for clinical purposes.

Keywords:
Positron emission tomography; Radiation dosimetry; Amyloid imaging; MIRD; [18F] FACT